Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27802495 | 0.90 | CHRNB2 (0.51) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL27779058 | 0.89 | ALDH1A1 (0.53) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL27778860 | 0.89 | ALDH1A1 (0.53) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL27778861 | 0.89 | ALDH1A1 (0.53) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL5190875 | 0.88 | ALDH1A1 (0.49) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL29976288 | 0.84 | ALDH1A1 (0.44) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL13535512 | 0.82 | CHRNB2 (0.56) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL5191569 | 0.79 | ALDH1A1 (0.47) | KMT2AALDH1A1MAPTHTTCHRNB2 | |
| SCHEMBL2479501 | 0.77 | MLNR (0.40) | — | |
| SCHEMBL12640183 | 0.76 | KMT2A (0.64) | KMT2AALDH1A1MAPTHTTCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649015-B2 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | KMT2A 3740/4885ALDH1A1 3337/4885MAPT 1076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.